JP2012528867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528867A5 JP2012528867A5 JP2012514047A JP2012514047A JP2012528867A5 JP 2012528867 A5 JP2012528867 A5 JP 2012528867A5 JP 2012514047 A JP2012514047 A JP 2012514047A JP 2012514047 A JP2012514047 A JP 2012514047A JP 2012528867 A5 JP2012528867 A5 JP 2012528867A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- nucleotide
- guanosine
- deaza
- cytosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18292809P | 2009-06-01 | 2009-06-01 | |
| US61/182,928 | 2009-06-01 | ||
| PCT/US2010/036923 WO2010141483A2 (en) | 2009-06-01 | 2010-06-01 | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528867A JP2012528867A (ja) | 2012-11-15 |
| JP2012528867A5 true JP2012528867A5 (https=) | 2017-09-07 |
| JP6275380B2 JP6275380B2 (ja) | 2018-02-07 |
Family
ID=43298446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514047A Expired - Fee Related JP6275380B2 (ja) | 2009-06-01 | 2010-06-01 | Ｔｌｒ７およびｔｌｒ９の免疫調節オリゴヌクレオチド（ｉｒｏ）アンタゴニストによる自己免疫および炎症性疾患治療の強化 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8987221B2 (https=) |
| EP (1) | EP2437791B1 (https=) |
| JP (1) | JP6275380B2 (https=) |
| CN (1) | CN102612561A (https=) |
| CA (1) | CA2762206C (https=) |
| ES (1) | ES2624767T3 (https=) |
| WO (1) | WO2010141483A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| KR101985382B1 (ko) | 2010-11-19 | 2019-06-03 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물 |
| US20130096938A1 (en) * | 2011-10-10 | 2013-04-18 | Abbott Biotechnology Ltd. | Managing healthcare services |
| WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| KR102027023B1 (ko) | 2012-11-29 | 2019-09-30 | 에스비아이 바이오테크 가부시키가이샤 | 저해성 올리고뉴클레오티드 및 그의 용도 |
| KR101898177B1 (ko) * | 2013-01-08 | 2018-09-12 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물 |
| EP2754714A1 (en) * | 2013-01-14 | 2014-07-16 | Sarepta Therapeutics, Inc. | Inhibitory oligonucleotides and their use in therapy |
| KR20170078843A (ko) | 2014-11-21 | 2017-07-07 | 노오쓰웨스턴 유니버시티 | 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수 |
| WO2017173334A1 (en) | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| US11339396B2 (en) | 2016-06-08 | 2022-05-24 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| US12246031B2 (en) | 2018-02-13 | 2025-03-11 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| KR102890791B1 (ko) | 2018-04-09 | 2025-11-24 | 체크메이트 파마슈티칼스, 인크. | 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
| US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| KR20080059595A (ko) * | 2005-09-27 | 2008-06-30 | 콜리 파마슈티칼 게엠베하 | 어댑터 올리고뉴클레오티드를 사용하는 ｔｌｒ-매개 면역반응의 조절 |
| US8426375B2 (en) * | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| ES2544877T3 (es) * | 2005-10-12 | 2015-09-04 | Idera Pharmaceuticals | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| US8383598B2 (en) * | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| PL2154144T3 (pl) * | 2008-08-06 | 2015-04-30 | Changchun Huapu Biotechnology Co Ltd | Oligonukleotydy i ich zastosowanie |
-
2010
- 2010-06-01 US US12/791,636 patent/US8987221B2/en active Active
- 2010-06-01 CN CN2010800243380A patent/CN102612561A/zh active Pending
- 2010-06-01 CA CA2762206A patent/CA2762206C/en active Active
- 2010-06-01 ES ES10783933.4T patent/ES2624767T3/es active Active
- 2010-06-01 EP EP10783933.4A patent/EP2437791B1/en not_active Not-in-force
- 2010-06-01 JP JP2012514047A patent/JP6275380B2/ja not_active Expired - Fee Related
- 2010-06-01 WO PCT/US2010/036923 patent/WO2010141483A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528867A5 (https=) | ||
| JP2010536787A5 (https=) | ||
| JP6406793B2 (ja) | トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物 | |
| JP6275380B2 (ja) | Ｔｌｒ７およびｔｌｒ９の免疫調節オリゴヌクレオチド（ｉｒｏ）アンタゴニストによる自己免疫および炎症性疾患治療の強化 | |
| US8853375B2 (en) | Toll like receptor modulators | |
| JP7461872B2 (ja) | 脂質ナノ粒子製剤における使用のための脂質 | |
| US9828601B2 (en) | Compositions for inhibiting checkpoint gene expression and uses thereof | |
| JP7478210B2 (ja) | 修飾オリゴヌクレオチド及び使用方法 | |
| JP5813778B2 (ja) | トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物 | |
| CA2879066C (en) | Chiral nucleic acid adjuvant | |
| US10604760B2 (en) | Combination comprising immunostimulatory oligonucleotides | |
| JP5761911B2 (ja) | Ｔｌｒ７およびｔｌｒ８に対する安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物 | |
| JP4942646B2 (ja) | 免疫賦活オリゴヌクレオチドマルチマー | |
| US20110009477A1 (en) | Oligonucleotide-based compounds as inhibitors of toll-like receptors | |
| JP2013544816A5 (https=) | ||
| CN102459302A (zh) | 核酸递送组合物及其使用方法 | |
| JP2015532097A5 (https=) | ||
| KR101898177B1 (ko) | 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물 | |
| JP2017528129A (ja) | 異常なレベル及び／又は活性のｉｆｐ３５ファミリーのタンパク質に関連する疾患又は障害を治療及び／又は予防するための方法及び組成物 | |
| JP2022010100A (ja) | Ｈｉｖの治療のための手段 | |
| JP2011515357A5 (https=) | ||
| JP2020521491A5 (https=) | ||
| JP6794258B2 (ja) | オリゴヌクレオチドについてのホスホロジアミデート骨格結合 | |
| CN112840026B (zh) | 抑制tigit基因表达的组合物和方法 |